Therefore, the improved ability of ticagrelor vs. thienopyridine P2Y12 blockers to improve peripheral endothelial function in CAD patients on DAPT may be limited to subjects with coexistent diabetes (mostly T2DM) regardless of whether platelet inhibition on ticagrelor was stronger [22, 25] or not [23, 26] compared to thienopyridines. The gene discussed is P2RY12; the disease is coronary artery disorder.